NCT03691584View on ClinicalTrials.gov

Phase 1, Safety and Bronchopulmonary PK Study in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

December 18, 2019

Conditions

Healthy Subjects

Interventions

DRUG

TP-6076

The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).

PROCEDURE

Bronchoalveolar lavage

Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.

Trial Locations (1)

Unknown

Hammersmith Medicines Research, London